Opus Genetics, Inc. Common Stock

IRDNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
4.03 USD
↘ 0.61 (13.15%)AT CLOSE (11:59 AM EDT)
4.04
↗ 0.01 (0.25%)
POST MARKET (AS OF 04:56 PM EDT)
Post Market
AS OF 04:56 PM EDT
4.04
↗ 0.01 (0.25%)
🔴Market: CLOSED
Open?$4.61
High?$4.61
Low?$4.02
Prev. Close?$4.64
Volume?1.0M
Avg. Volume?963.6K
VWAP?$4.23
Rel. Volume?1.06x
Bid / Ask
Bid?$3.50 × 100
Ask?$5.53 × 100
Spread?$2.03
Midpoint?$4.52
Valuation & Ratios
Market Cap?328.0M
Shares Out?81.4M
Float?56.1M
Float %?78.9%
P/E Ratio?N/A
P/B Ratio?-7.16
EPS?-$1.31
Dividend?0.00%
Ex-Dividend?N/A

IRD is currently priced at $4.03. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Strong Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (233.3%) and a bullish Golden Cross on the moving averages. On the valuation front, IRD trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
28
Market Cap
328.0M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.opusgtx.com
Listed
2020-11-06
Address
8 DAVIS DRIVE
DURHAM, NC 27713
Phone: 248-681-9815
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookStrong Sell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
23
Short Sent.?
39
Piotroski F-Score?0/9Weak
Altman Z-Score?-4.01Distress
Confidence?60%Moderate
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?5.54%Elevated
Short Interest?3.1M
Days to Cover?3.2
Free Float56.1M
Avg Daily Volume971.6K
Settlement Date2026-05-15
Financial Health
Current Ratio?7.13Strong
Quick Ratio?7.13Strong
Cash Ratio?6.42Strong
Debt/Equity?-0.03Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
S&P
97
-7.16CHEAP▾
P/S?
Peers
100
S&P
3
27.37HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-6.3CHEAP▾
EV/Sales?
Peers
100
S&P
3
22.47HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
97
233.3%STRONG▾
ROA?
S&P
3
-160.1%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$269.3M
Fundamentals ratios updated end of day
MarketsMoversWatchlist